Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis
- PMID: 36753419
- DOI: 10.1016/j.celrep.2023.112058
Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis
Abstract
Senescent cells can spread the senescent phenotype to other cells by secreting senescence-associated secretory phenotype factors. The resulting paracrine senescent cells make a significant contribution to the burden of senescent cell accumulation with age. Previous efforts made to characterize paracrine senescence are unreliable due to analyses being based on mixed populations of senescent and non-senescent cells. Here, we use dipeptidyl peptidase-4 (DPP4) as a surface maker to isolate senescent cells from mixed populations. Using this technique, we enrich the percentage of paracrine senescence from 40% to 85%. We then use this enriched culture to characterize DPP4+ primary and paracrine senescent cells. We observe ferroptosis dysregulation and ferrous iron accumulation as a common phenomenon in both primary and paracrine senescent cells. Finally, we identify ferroptosis induction and ferrous iron-activatable prodrug as a broad-spectrum senolytic approach to ablate multiple types of primary and paracrine senescent cells.
Keywords: CP: Cell biology; ferroptosis; ferrous; iron; paracrine senescence; prodrug; senescence.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.P.M. is an advisor/consultant for the Longevity Vision Fund, NOVOS, Youth Bio Therapeutics, and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. A.R.R. is a co-founder of Tatara Therapeutics Inc., which is developing iron-activated therapeutics.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
